Pedro de Pablos

List of Publications by Year
in descending order

55 papers	2,455 citations	257357 24 h-index	206029 48 g-index
71 all docs	71 docs citations	71 times ranked	3392 citing authors

#	Article	IF	Citations
1	Age- and Sex-Specific Prevalences of Diabetes and Impaired Glucose Regulation in 13 European Cohorts. Diabetes Care, 2003, 26, 61-69.	4.3	486
2	Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). European Journal of Endocrinology, 2004, 151, 439-446.	1.9	334
3	Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clinical Endocrinology, 2014, 80, 47-56.	1.2	168
4	Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. European Journal of Endocrinology, 2006, 155, 269-277.	1.9	166
5	Predictors of Quality of Life and Other Patient-Reported Outcomes in the PANORAMA Multinational Study of People With Type 2 Diabetes. Diabetes Care, 2018, 41, 267-276.	4.3	81
6	Bone mineral metabolism is normal in non-insulin-dependent diabetes mellitus. Journal of Diabetes and Its Complications, 1996, 10, 201-205.	1.2	79
7	Prevalence and determinants of diabetes mellitus and glucose intolerance in a Canarian Caucasian population - comparison of the 1997 ADA and the 1985 WHO criteria.â€ƒThe GuÃa Study.. Diabetic Medicine, 2001, 18, 235-241.	1.2	63
8	Consensus document for the detection and management of chronic kidney disease. Nefrologia, 2014, 34, 243-62.	0.2	61
9	Obesity and cardiovascular disease. Public Health Nutrition, 2007, 10, 1156-1163.	1.1	56
10	Blood lipid levels in relation to glucose status in European men and women without a prior history of diabetes: The DECODE Study. Diabetes Research and Clinical Practice, 2008, 82, 364-377.	1.1	44
11	N1-methylnicotinamide is a signalling molecule produced in skeletal muscle coordinating energy metabolism. Scientific Reports, 2018, 8, 3016.	1.6	42
12	Quality of life and satisfaction with treatment in subjects with type 2 diabetes: Results in Spain of the PANORAMA study. EndocrinologÃa Y NutriciÃ³n (English Edition), 2014, 61, 18-26.	0.5	40
13	PANORAMA: A European study to evaluate quality of life and treatment satisfaction in patients with type-2 diabetes mellitusâ€”Study design. Primary Care Diabetes, 2011, 5, 231-239.	0.9	39
14	Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. Diabetes, Obesity and Metabolism, 2015, 17, 170-178.	2.2	36
15	Prevalence of distal diabetic polyneuropathy using quantitative sensory methods in a population with diabetes of more than 10 yearsâ€™ disease duration. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2010, 57, 414-420.	0.8	33
16	Nateglinide Improves Early Insulin Secretion and Controls Postprandial Glucose Excursions in a Prediabetic Population. Diabetes Care, 2002, 25, 2141-2146.	4.3	30
17	Is sprint exercise a leptin signaling mimetic in human skeletal muscle?. Journal of Applied Physiology, 2011, 111, 715-725.	1.2	29
18	Skeletal muscle signaling response to sprint exercise in men and women. European Journal of Applied Physiology, 2012, 112, 1917-1927.	1.2	28

#	Article	IF	Citations
19	Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. Journal of Diabetes and Its Complications, 2014, 28, 40-44.	1.2	28
20	Obesity Surgery Score (OSS) for Prioritization in the Bariatric Surgery Waiting List: a Need of Public Health Systems and a Literature Review. Obesity Surgery, 2018, 28, 1175-1184.	1.1	28
21	Bimodal Distribution of Glucose Is Not Universally Useful for Diagnosing Diabetes. Diabetes Care, 2009, 32, 397-403.	4.3	24
22	Hypoglycaemic episodes in patients with type 2 diabetesÂâ€“Ârisk factors and associations with patient-reported outcomes: The PANORAMA Study. Diabetes and Metabolism, 2015, 41, 470-479.	1.4	24
23	Prevalence of obesity in a Canarian community. Association with type 2 diabetes mellitus: the GuÃa Study. European Journal of Clinical Nutrition, 2002, 56, 557-560.	1.3	23
24	Effectiveness and cost-effectiveness of knowledge transfer and behavior modification interventions in type 2 diabetes mellitus patientsâ€"the INDICA study: a cluster randomized controlled trial. Implementation Science, 2015, 10, 47.	2.5	19
25	Patterns of prescription of hypoglycaemic drugs in Gran Canaria (Canary Islands, Spain) and estimation of the prevalence of diabetes mellitus. Diabetes and Metabolism, 2005, 31, 457-462.	1.4	18
26	Exercise Mitigates the Loss of Muscle Mass by Attenuating the Activation of Autophagy during Severe Energy Deficit. Nutrients, 2019, 11, 2824.	1.7	18
27	Brown tumor in the palate associated with primary hyperparathyroidism. Journal of Oral and Maxillofacial Surgery, 1987, 45, 719-720.	0.5	17
28	Effectiveness of Internet-Based Multicomponent Interventions for Patients and Health Care Professionals to Improve Clinical Outcomes in Type 2 Diabetes Evaluated Through the INDICA Study: Multiarm Cluster Randomized Controlled Trial. JMIR MHealth and UHealth, 2020, 8, e18922.	1.8	17
29	Prevalence, awareness, treatment and control of hypertension in a Canarian population. Relationship with glucose tolerance categories. The GuÃa Study. Journal of Hypertension, 2002, 20, 1965-1971.	0.3	16
30	ViDa1: The Development and Validation of a New Questionnaire for Measuring Health-Related Quality of Life in Patients with Type 1 Diabetes. Frontiers in Psychology, 2017, 8, 904.	1.1	16
31	Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse Î²-cell function in the GetGoal-M and GetGoal-S trials. Journal of Diabetes and Its Complications, 2016, 30, 1385-1392.	1.2	15
32	Pioglitazone: beyond glucose control. Expert Review of Cardiovascular Therapy, 2010, 8, 1057-1067.	0.6	14
33	Mitochondrial Complex I Inhibition by Metformin: Drugâ€"Exercise Interactions. Trends in Endocrinology and Metabolism, 2020, 31, 269-271.	3.1	14
34	Effectiveness of lanreotide autogel 120â€‰mg at extended dosing intervals for acromegaly. Endocrine, 2020, 70, 575-583.	1.1	12
35	Angiotensinâ€Converting Enzyme 2 (SARSâ€CoVâ€2 receptor) expression in human skeletal muscle. Scandinavian Journal of Medicine and Science in Sports, 2021, 31, 2249-2258.	1.3	12
36	Losartan titration versus diuretic combination in type 2 diabetic patients. Journal of Hypertension, 2002, 20, 715-719.	0.3	11

#	Article	IF	Citations
37	Effects of Losartan and Diltiazem on Blood Pressure, Insulin Sensitivity, Lipid Profile and Microalbuminuria in Hypertensive Type 2 Diabetic Patients. Clinical Drug Investigation, 1998, 16, 361-370.	1.1	10
38	Blood pressure, antihypertensive treatment and factors associated with good blood pressure control in hypertensive diabetics: the Tarmidas study. Journal of Human Hypertension, 2007, 21, 664-672.	1.0	10
39	Protein synthesis signaling in skeletal muscle is refractory to whey protein ingestion during a severe energy deficit evoked by prolonged exercise and caloric restriction. International Journal of Obesity, 2019, 43, 872-882.	1.6	10
40	Resting metabolic rate is increased in hypertensive patients with overweight or obesity: Potential mechanisms. Scandinavian Journal of Medicine and Science in Sports, 2021, 31, 1461-1470.	1.3	10
41	Sarcolipin expression in human skeletal muscle: Influence of energy balance and exercise. Scandinavian Journal of Medicine and Science in Sports, 2020, 30, 408-420.	1.3	8
42	Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey. Pituitary, 2020, 23, 129-139.	1.6	8
43	Prevalence of hypertension in IDDM patients in the Northern Grand Canary Island, according to the WHO/ISH and JNC-V/ADA criteria. Diabetes Research and Clinical Practice, 1997, 38, 191-197.	1.1	7
44	Empagliflozin in combination with oral agents in young and overweight/obese Type 2 diabetes mellitus patients: A pooled analysis of three randomized trials. Journal of Diabetes and Its Complications, 2016, 30, 1571-1576.	1.2	7
45	Isoinertial and Isokinetic Sprints: Muscle Signalling. International Journal of Sports Medicine, 2013, 34, 285-292.	0.8	5
46	Resting Energy Expenditure and Body Composition in Overweight Men and Women Living in a Temperate Climate. Journal of Clinical Medicine, 2020, 9, 203.	1.0	4
47	The Relation Between Physical Activity and Metabolic Control in Type 2 Diabetes With <20 Years of Evolution. Diabetes Care, 2003, 26, 1648-1650.	4.3	3
48	Adiponectin: An Emerging Cardiovascular Risk Factor. The REFERENCE Study. Revista Espanola De Cardiologia (English Ed), 2008, 61, 1159-1167.	0.4	3
49	Glucagon-like peptide-1 receptor agonists as insulin add-on therapy in patients with inadequate glycemic control in type 2 diabetes mellitus: lixisenatide as a new therapeutic option. International Journal of Clinical Pharmacology and Therapeutics, 2015, 53, 230-240.	0.3	3
50	Pancreatic beta cell function is preserved in the short term in patients with type 2 diabetes undergoing non-urgent surgery. Minerva Endocrinology, 2018, 43, 109-116.	0.6	1
51	Treatment of hypertension with angiotensinâ€converting enzyme inhibitors or angiotensin receptor blockers and resting metabolic rate: A crossâ€sectional study. Journal of Clinical Hypertension, 2021, 23, 2106.	1.0	1
52	PDB28 DIABETES MELLITUS BURDEN AND RELATIONSHIP WIHTHE DEGREE OF PATIENTxS GLYCEMIC CONTROL. Value in Health, 2008, 11, A504-A505.	0.1	0
53	PDB49 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND TREATMENT SATISFACTION (TS) IN DIABETIC PATIENTS ATTENDED IN SPANISH PRIMARY CARE CENTRES. Value in Health, 2008, 11, A511-A512.	0.1	0
54	Saxagliptina, un nuevo inhibidor de la DPP-4 en el tratamiento de la diabetes mellitus tipo 2: aspectos novedosos. Avances En DiabetologÃa, 2010, 26, 445-447.	0.1	0

#	Article	IF	Citations
55	Adjunctive Lixisenatide Treatment Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus Irrespective of Î²-cell Function. Canadian Journal of Diabetes, 2014, 38, S50-S51.	0.4	0